Concepedia

Andrew F. Donnell

AF

Statistics

Publications

8

Citations

236

H-Index

8

Active since

2005

Affiliations

Bristol-Myers Squibb (United States)(Current)

Indiana University Bloomington

Andrew F. Donnell is an author at Bristol-Myers Squibb (United States) specializing in medicinal chemistry, drug discovery, and organic chemistry.

ORCID

Publications per year

2005–2022

8

Publications

8

Total Synthesis of (+)‐Apiosporamide: Assignment of Relative and Absolute Configuration

David R. Williams, David C. Kammler, Andrew F. Donnell et al. · Angewandte Chemie International Edition · 2005 · 54 citations

, , +10

Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors

Andrew F. Donnell, Paul Dollings, John A. Butera et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 39 citations · Full text

, , +8

Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain

Robert F. Kester, Andrew F. Donnell, Yan Lou et al. · Journal of Medicinal Chemistry · 2013 · 38 citations · Full text

, , +16

Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain

Andrew F. Donnell, Christophe Michoud, Kenneth C. Rupert et al. · Journal of Medicinal Chemistry · 2013 · 28 citations · Full text

, , +15

Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents

Yong Zhang, Yufen Zhao, Andrew J. Tebben et al. · ACS Medicinal Chemistry Letters · 2018 · 28 citations · Full text

, , +17

1–5 of 8